フジワラ　アツシ   Atsushi Fujiwara   藤原　篤之    所属   川崎医療福祉大学  リハビリテーション学部 視能療法学科    職種   講師
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	Results of a Treat-and-Eextend Regimen of Intravitreal Ranibizumab Injection for Macular Edema due to Branch Retinal Vein Occlusion.
掲載誌名	正式名：Acta medica Okayama 略　 称：Acta Med Okayama ISSNコード：0386300X/0386300X
掲載区分	国外
巻・号・頁	72(1),pp.39-45
著者・共著者	Hosogi Mika, Morizane Yuki, Shiode Yusuke, Doi Shinichiro, Kumase Fumiaki, Kimura Shuhei, Hosokawa Mio, Hirano Masayuki, Toshima Shinji, Takahashi Kosuke, Fujiwara Atsushi, Shiraga Fumio
発行年月	2018/02
概要	To investigate the effectiveness of a treat-and-extend regimen (TAE) of intravitreal ranibizumab injections (IVR) for macular edema (ME) due to branch retinal vein occlusion (BRVO). We retrospectively examined 35 eyes of 35 patients with ME due to BRVO who underwent TAE for 1 year. Patients whose treatment interval extended to 12 weeks were switched to a pro re nata regimen (PRN; TAE to PRN group), while TAE was continued for patients whose treatment interval was less than 12 weeks (continued TAE group). Changes in best-corrected visual acuity (BCVA), central retinal thickness (CRT), and predictive factors for inclusion in the TAE to PRN group were analyzed. BCVA and CRT both improved significantly at 1 year compared with baseline (p<0.001). Sixteen eyes (45.7%) were included in the TAE to PRN group, while 19 eyes (54.3%) were included in the continued TAE group. BCVA in the TAE to PRN group was significantly better than that in the continued TAE group at 1 year (p=0.047). BCVA at baseline and macular BRVO were significant predictive factors for inclusion in the TAE to PRN group. TAE was effective for improving BCVA and CRT. The TAE to PRN group showed significantly better prognosis.
DOI	10.18926/AMO/55661
PMID	29463937